Evolus, Inc. (NasdaqGM: EOLS)
Health Care · Pharmaceuticals · US
$8.68
+3.46% today · +12.9% 1Y
Evolus, Inc. (NasdaqGM: EOLS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $554.16M and employs 350 people.
Over the last twelve months the share price has gained 12.9%, trading between 3.86 and 8.69.
Tweenvest scores Evolus, Inc. across four factors: quality 30/100, value 68/100, growth 100/100. Its strongest factor is growth.
EOLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $554.16M
- Revenue (TTM)
- $316.49M
- P/E
- —
- EPS
- -0.53
- Dividend yield
- —
- Beta (5Y)
- 1.36
- 52-week high
- $8.69
- 52-week low
- $3.86
- Avg volume (3M)
- —
- Shares outstanding
- 66.05M
- Employees
- 350
- Next earnings
- —
About Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
- ISIN
- US30052C1071
- Founded
- 2012
- Listed since
- Feb 8, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.02 | -0.75% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.63 | +0.88% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.68 | -1.23% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.04 | -0.12% |
Figures last refreshed Aug 18, 2026.